ABT stock forecast, quote, news & analysis

Key Takeaways

• Abbott Laboratories (ABT) traded near $103.70 in late October 2026, up roughly 2.6% over the trailing 30 days after a choppy stretch for the stock.
• The shares pulled back from above $116 in late August to the mid-$90s in early October before stabilizing and recovering modestly into earnings season.
• Third-quarter 2026 revenue rose 14.5% year over year to $13.01 billion, with comparable sales up 7.0% and adjusted EPS of $1.42.
• Abbott announced plans to separate its Nutrition business into an independent public company, expected to be completed by the end of 2027.
• Management lowered full-year 2026 comparable sales growth guidance to approximately 6% and narrowed adjusted EPS guidance to $5.50–$5.55.
• BTIG lowered its price target to $125 from $134 while maintaining a Buy rating following the third-quarter report.
• For deeper research, explore Abbott's Price Targets, Earnings, and Forecast pages.
• Discover automated trading strategies on Tickeron's Trending AI Robots page.

Current Market Snapshot

Abbott shares have been in a consolidation phase after a notable late-summer decline. The stock traded above $116 in late August 2026 before selling off through September and touching the mid-$90s in early October, a drawdown that coincided with broader defensive-sector repositioning and softer sentiment ahead of third-quarter results. Over the trailing 30 days, however, the stock recovered about 2.6%, moving from near $101 to roughly $103.70, as investors digested the company's quarterly report and its newly announced portfolio restructuring. The reaction underscores a measured market response: Abbott's fundamental growth remains intact, but near-term headwinds in diabetes care and electrophysiology have tempered enthusiasm.

Abbott Laboratories (ABT) Business Overview and Competitive Position

Abbott Laboratories is a diversified global healthcare company operating across four segments: Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition. The company is best known for its FreeStyle Libre continuous glucose monitoring franchise, alongside cardiovascular, electrophysiology, and neuromodulation devices. Its Diagnostics business, strengthened by the Exact Sciences acquisition, spans core laboratory, molecular, and cancer diagnostics, including the Cologuard colorectal cancer screening test. Nutrition brands such as Similac, Ensure, and Pedialyte round out a portfolio that generates balanced, recurring revenue across developed and emerging markets. This diversification gives Abbott defensive cash-flow characteristics and multiple innovation-driven growth avenues, which is why the stock is widely followed by both growth and income investors.

Recent Developments Driving ABT

The most significant development of the past month was Abbott's decision to separate its Nutrition business into an independent, publicly traded company by the end of 2027. The segment generates roughly $8.5 billion in annual sales, and management projects the separation will accelerate Abbott's overall sales growth by 50–100 basis points while lifting operating margin by approximately 100 basis points. The move reflects a strategic focus on higher-growth healthcare categories, though it leaves lingering litigation related to infant nutrition as a consideration for both entities.

The third-quarter earnings release, published October 21, 2026, also shaped sentiment. Comparable sales grew 7.0%, with Medical Devices up 7.8% on a comparable basis and Diagnostics up 6.4%. Electrophysiology advanced 15.5%, driven by the Volt pulsed field ablation catheter, while cancer diagnostics grew 13.8% on Cologuard and precision oncology strength. However, management reduced full-year comparable sales growth guidance to about 6% from a prior 6.5%–7.5% range, citing temporary electrophysiology and diabetes care headwinds. Diabetes growth is expected to slow to low-to-mid single digits amid international pricing pressure and limited type 2 reimbursement expansion, while electrophysiology faces softer left atrial appendage demand ahead of the Amulet 360 launch.

Regulatory momentum continued, with FDA approval of the Libre Duo dual glucose-ketone sensor in August and the TactiFlex Duo ablation catheter in September, plus the launch of the SimpleScreen CRC blood-based colorectal cancer screening test.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies drawn from a broader library of hundreds of AI-driven bots that monitor thousands of tickers. Only the top-performing and most relevant robots are featured in this section, giving traders a focused view of strategies that are currently demonstrating strength. The bots vary widely in approach, holding timeframe, and performance metrics, so users can compare different methodologies rather than relying on a single signal. For investors tracking names like Abbott alongside the broader market, the page offers a convenient way to explore data-driven, algorithm-based trading ideas in one place.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors will shape Abbott's trajectory. The execution and timing of the Nutrition separation will remain a central theme, with investors watching for details on capital structure, dividend policy, and the standalone entity's financial profile. Diabetes care is another key swing factor: the planned U.S. launch of Libre Duo in December 2026 and a favorable payer formulary win effective January 1, 2027 could re-accelerate growth, while international pricing pressure remains a near-term drag. In electrophysiology, the Amulet 360 device launch and continued Volt and TactiFlex Duo adoption will be closely monitored. Diagnostics, particularly cancer diagnostics growth, will depend on Cologuard momentum and integration of the Exact Sciences portfolio. Broader considerations include China volume-based procurement pressures, ongoing infant nutrition litigation, and how management frames 2027 guidance when it is introduced in January. These catalysts present a balanced mix of execution risks and innovation-led growth opportunities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations